Last reviewed · How we verify

NCT04712006

A Study of JNJ-64304500 Following Subcutaneous Injection in Healthy Chinese Adult Participants

Withdrawn Phase 1 Last updated 1 September 2021
What this trial tests

Phase 1 trial testing JNJ-64304500 in Healthy. Withdrawn.

Timeline
30 May 2021
Primary endpoint
27 August 2021
30 October 2021

Quick facts

Lead sponsorJanssen Research & Development, LLC
PhasePhase 1
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationnon randomized
Designsequential
Maskingnone
Primary purposetreatment
Start date30 May 2021
Primary completion27 August 2021
Estimated completion30 October 2021
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Janssen Research & Development, LLC — full company profile →

Who can join

Adults 18 to 55, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess the pharmacokinetic following single subcutaneous administration of Dose 1 or Dose 2 of JNJ-64304500 in healthy Chinese adult participants.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of JNJ-64304500

Trials testing the same drug.

Other recruiting trials for Healthy

Currently open trials in the same condition.

Other Janssen Research & Development, LLC trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04712006.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing